Last reviewed · How we verify

Supraclavicular Block

Weill Medical College of Cornell University · FDA-approved active Small molecule Under review

Supraclavicular Block is a Small molecule drug developed by Weill Medical College of Cornell University. It is currently FDA-approved for Anesthesia for upper extremity surgery (shoulder, arm, forearm, hand procedures), Postoperative pain management for upper extremity surgery.

A supraclavicular block is a regional anesthesia technique that interrupts nerve conduction in the upper trunk of the brachial plexus by injecting local anesthetic near the supraclavicular fossa.

A supraclavicular block is a type of regional anesthesia used to manage pain in the upper limb, particularly during surgeries such as elbow surgeries. This block involves the administration of local anesthetics, which can be enhanced by adjuvants like dexmedetomidine, to achieve high-quality analgesia.

At a glance

Generic nameSupraclavicular Block
SponsorWeill Medical College of Cornell University
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhaseFDA-approved

Mechanism of action

This procedure involves the percutaneous injection of local anesthetic agents (such as lidocaine or bupivacaine) around the upper portion of the brachial plexus as it passes through the supraclavicular region. The anesthetic diffuses into nerve tissue, blocking sodium channels and preventing action potential propagation, thereby producing sensory and motor blockade of the upper extremity. This technique is used to provide anesthesia for surgical procedures on the shoulder, arm, and hand.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Supraclavicular Block

What is Supraclavicular Block?

Supraclavicular Block is a Small molecule drug developed by Weill Medical College of Cornell University, indicated for Anesthesia for upper extremity surgery (shoulder, arm, forearm, hand procedures), Postoperative pain management for upper extremity surgery.

How does Supraclavicular Block work?

A supraclavicular block is a regional anesthesia technique that interrupts nerve conduction in the upper trunk of the brachial plexus by injecting local anesthetic near the supraclavicular fossa.

What is Supraclavicular Block used for?

Supraclavicular Block is indicated for Anesthesia for upper extremity surgery (shoulder, arm, forearm, hand procedures), Postoperative pain management for upper extremity surgery.

Who makes Supraclavicular Block?

Supraclavicular Block is developed and marketed by Weill Medical College of Cornell University (see full Weill Medical College of Cornell University pipeline at /company/weill-medical-college-of-cornell-university).

What development phase is Supraclavicular Block in?

Supraclavicular Block is FDA-approved (marketed).

What are the side effects of Supraclavicular Block?

Common side effects of Supraclavicular Block include Horner's syndrome, Phrenic nerve palsy, Recurrent laryngeal nerve injury, Local anesthetic toxicity, Vascular puncture, Hematoma.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing